Asthma Therapeutics in Major Developed Markets Growth & Trend to 2020 Radiant Insights, Inc
Summary Radiant Insights, a leading business intelligence provider, has released its latest research report,"Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence. The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025. Access This Full Report @ http://www.radiantinsights.com/research/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest. Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.
Summary
Radiant Insights, a leading business intelligence provider, has released its latest research report,"Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.
The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.
Access This Full Report @ http://www.radiantinsights.com/research/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations
Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.
Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Figure 19: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Phase III Cl<strong>in</strong>ical Trial Recruitment Size by Molecular<br />
Target (participants), 2006–2014 69<br />
Figure 20: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Failure Rate (%), Average Cl<strong>in</strong>ical Trial Duration<br />
(months) and Average Recruitment Size for <strong>Asthma</strong> by Molecule Type, 2006–2014 70<br />
Figure 21: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global Failure Rate (%), Average Cl<strong>in</strong>ical Trial Duration<br />
(months) and Average Trial Recruitment Size (participants) for <strong>Asthma</strong> by Molecular Target, 2006–2014<br />
70<br />
Figure 22: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Mepolizumab Forecast ($bn), 2015–<strong>2020</strong> 73<br />
Figure 23: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Reslizumab Forecast ($bn), 2016–<strong>2020</strong> 75<br />
Figure 24: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Lebrikizumab Forecast ($m), 2018–<strong>2020</strong> 76<br />
Figure 25: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Dupilumab Forecast ($m), 2018–<strong>2020</strong> 79<br />
Figure 26: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Masit<strong>in</strong>ib Forecast ($m), 2017–<strong>2020</strong> 81<br />
Figure 27: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Heat Map for Pipel<strong>in</strong>e Products, 2015 81<br />
Access This Full Report @ http://www.radiant<strong>in</strong>sights.com/research/asthma-therapeutics-<strong>in</strong>major-developed-markets-<strong>to</strong>-<strong>2020</strong>-personalized-treatment-for-severe-asthma-<strong>to</strong>-drive-marketgrowth-despite-patent-expirations<br />
Figure 28: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Competi<strong>to</strong>r Matrix for Marketed and Pipel<strong>in</strong>e Products,<br />
2015 82<br />
Figure 29: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Treatment Patterns, 2013–<strong>2020</strong> 86<br />
Figure 30: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Market Size ($bn), 2013–<strong>2020</strong> 87<br />
Figure 31: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, North America, Treatment Patterns, 2013–<strong>2020</strong> 89<br />
Figure 32: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, North America, Annual Cost of Therapy ($), 2013–<strong>2020</strong> 91<br />
Figure 33: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, North America, Market Size, 2013–<strong>2020</strong> 93<br />
Figure 34: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Top Five EU Countries, Treatment Patterns, 2013–<strong>2020</strong> 94<br />
Figure 35: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Top Five EU Countries, Annual Cost of Therapy ($), 2013–<strong>2020</strong><br />
96<br />
Figure 36: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Top Five EU Countries, Market Size, 2013–<strong>2020</strong> 97<br />
Figure 37: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Japan, Treatment Patterns, 2013–<strong>2020</strong> 98<br />
Figure 38: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Japan, Annual Cost of Therapy ($), 2013–<strong>2020</strong> 99
Change language